CHP
CRVS icon

Cable Hill Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Cable Hill Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-250
Closed -$3K – 797
2018
Q2 		$3K Sell
250
-750
-75% -$8.37K ﹤0.01% 765
2018
Q1 		$10K Buy
+1,000
New +$9.46K ﹤0.01% 483
2017
Q4 		– Sell
-800
Closed -$13K – 946
2017
Q3 		$13K Hold
800
– – 0.01% 510
2017
Q2 		$10K Hold
800
– – 0.01% 404
2017
Q1 		$17K Hold
800
– – 0.01% 280
2016
Q4 		$11K Hold
800
– – 0.01% 381
2016
Q3 		$13K Buy
800
+400
+100% +$5.77K 0.01% 361
2016
Q2 		$6K Buy
+400
New +$5.4K ﹤0.01% 464

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CI
Cowen Inc New York $1.35B AUM 60.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return